Coloplast AS (CLPBF) Q4 2025 Earnings Call Highlights: Strategic Restructuring and Growth Challenges
This article first appeared on GuruFocus .
Release Date: November 04, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Coloplast AS ( CLPBF ) achieved 7% organic growth, aligning with revised guidance.
-
The company restructured its business in China to align with new market realities, ensuring a sustainable presence.
-
Significant changes at the group level, including structuring into chronic and acute care units, are expected to enhance strategy execution towards 2030.
-
The company has a strong product portfolio and is well-positioned to capture opportunities in a market valued at over 120 billion Danish kroner.
-
Coloplast AS ( CLPBF ) is investing in technology and AI to improve user experience and operational efficiency.
Negative Points
-
Organic growth was below the initial expectation of 8-9%, indicating challenges in meeting earlier projections.
-
Product recalls in interventional urology and advanced wound dressings significantly impacted performance.
-
Increased volatility in the biotics market due to policy postponements led to a slowdown in momentum.
-
Sales in China declined due to weaker consumer sentiment and competitive pressures.
-
The company faced high special item expenses related to profitability improvement initiatives, impacting overall financial performance.
Q & A Highlights
Q: Can you discuss the China ostomy business and the increased competition in the community channel? How is consumer sentiment affecting your business development plans for 2026? A: (Interim CEO) The growth in China is flat, and while we remain competitive, consumer sentiment is negative, impacting spending. The market share remains low, and competition hasn't increased significantly. Our competitiveness is intact, but the market sentiment is the main reason for the lack of growth.
Q: What are the drivers for the Kereis margin improvement this year, and how do you see this evolving given the reimbursement changes? A: (Interim CEO) We expect a better margin due to scaling and a more mature business model. While there is volatility due to recent reimbursement changes, we consider these changes positive for us in the long term.
Q: Regarding the AOS integration, what's left to do, and when will the benefits start to materialize? A: (CFO) We are finalizing the integration into our IT infrastructure and processes, focusing on major markets like the US and UK. We expect to complete this during the financial year and realize synergies of around 100 million Danish kroner.
Q: How confident are you in achieving your back-end loaded guidance for this year, and what ASP development have you assumed? A: (CFO) We expect organic growth of around 7%, with some headwinds in Q1 due to product recalls. We are confident in our guidance, supported by strong performance in the continence and Kereis businesses. We anticipate a small positive ASP impact, particularly in urology and emerging markets.
Q: Can you elaborate on the competitive bidding program in the US for chronic care products and its potential impact? A: (CFO) We expect any impact from the competitive bidding program to occur in 2028 at the earliest. Regarding the wound recall impact in China, we estimate a negative impact of around 25 million Danish kroner per quarter for Q1, Q2, and Q3 of 2026.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
